Pulmonary-Allergy Drugs
Executive Summary
At July 23 meeting, the FDA Advisory Committee will discuss two lung surfactant extracts: Burroughs Wellcome's synthetic extract Exosurf (colfosceril palmitate) and Survanta (beractant), a bovine lung surfactant TA from Abbott's Ross Labs subsidiary. Both products are currently available under Treatment INDs for respiratory distress syndrome in premature infants (also called hyaline membrane disease), an orphan indication. Exosurf received a Treatment IND in July 1989; Survanta in October 1989.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.